ClinicalTrials.gg
Active, not recruitingNCT07329725ThrombosisUpdated Jan 9, 2026

Genetic Drivers,Risk Factors and Management Strategies on Survival and Clinical Outcomes in Visceral Venous "Thrombosis"

An observational study in Visceral Venous Thrombosis, sponsored by Sohag University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
101
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Venous Thrombosis with a site in Egypt — 2 open to participants now, 4 under way, none of them phase 3. Venous Thrombosis · Egypt.

Started
2025
with 1 other
Observational
3 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Sohag University

Among the 10 studies in Venous Thrombosis with a site in Egypt, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 8th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

2 of the 10 studies in Venous Thrombosis with a site in Egypt are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Venous Thrombosis with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the impact of genetic drivers (somatic and inherited thrombophilias), acquired risk factors, and management strategies on survival and clinical outcomes in patients with VVT using a hybrid prospective-retrospective cohort design.

Read the detailed description

Observational study (hybrid study comprising a retrospective and prospective cohort analysis):

To evaluate the impact of genetic drivers (somatic and inherited thrombophilias), acquired risk factors, and management strategies on survival and clinical outcomes in patients with VVT using a hybrid prospective-retrospective cohort design.

Data will be collected from the Department of Internal Medicine/hematology unit at Sohag University hospital and clinical databases.

The retrospective component will include eligible patients diagnosed within the preceding ten years, whereas the prospective component will enroll newly diagnosed patients and follow them for one year.

  1. Retrospective Cohort Analysis:

    Review of medical records to analyze demographic, clinical, and molecular data. Assessment of treatment regimens and outcomes, including thrombotic events, disease progression, and survival rates.

  2. Prospective Cohort Analysis:

Consecutive patients will be diagnosed with VVT from [date of ethical approval] forward, enrolled at diagnosis and followed prospectively with standardized baseline testing (including comprehensive genetic panel) and predefined follow-up visits.

03

Conditions studied

  • Visceral Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients diagnosed with visceral venous thrombosis, including portal, mesenteric, splenic, renal and hepatic vein thrombosis in Department of Internal Medicine, Sohag University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years) with radiologically confirmed visceral venous thrombosis.
  • Availability of complete clinical, laboratory, and imaging data at diagnosis.
  • Patients who consent to participate and provide blood samples for genetic testing.

Exclusion criteria

Exclusion Criteria:

  • Isolated lower-limb deep-vein thrombosis or pulmonary embolism without visceral involvement.
  • Patients with incomplete records precluding outcome assessment.
  • Refusal or inability to provide
  • Patients lost to follow-up within the first three months of diagnosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
101 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Retrospective Cohort Analysis

    Review of medical records to analyze demographic, clinical, and molecular data. Assessment of treatment regimens and outcomes, including thrombotic events, disease progression, and survival rates.

    Other: Doppler ultrasonography

  • Prospective Cohort Analysis

    Consecutive patients will be diagnosed with VVT from \[date of ethical approval\] forward, enrolled at diagnosis and followed prospectively with standardized baseline testing (including comprehensive genetic panel) and predefined follow-up visits.

    Other: Doppler ultrasonography

Interventions

  • OtherDoppler ultrasonography

    Radiological intervention Basic laboratory investigations, and Thrombophilia diagnosis

    Also known as: Chest-X ray, Electrocardiogram (ECG), Echocardiography if indicated., CT angiography, MR venography, Doppler of the limbs, Basic laboratory investigations, Thrombophilia diagnosis

06

What researchers measure

Primary outcomes

  1. Patients diagnosed with visceral venous thrombosis

    To evaluate the impact of genetic drivers (somatic and inherited thrombophilias), acquired risk factors, and management strategies on survival and clinical outcomes in patients with VVT using a hybrid prospective-retrospective cohort design.

    Time frame: The retrospective component will include eligible patients diagnosed within the preceding ten years, whereas the prospective component will enroll newly diagnosed patients and follow them for one year.

Secondary outcomes

  1. Frequency and distribution

    To estimate the frequency of somatic mutations and inherited thrombophilias and describe their distribution across anatomical sites of VVT (portal, mesenteric, renal, splenic, hepatic) and underlying etiologies (autoimmune, inflammation, cirrhosis, malignancy, post-surgery, idiopathic).

    Time frame: The retrospective component will include eligible patients diagnosed within the preceding ten years, whereas the prospective component will enroll newly diagnosed patients and follow them for one year.

07

Study locations

1 site
08

References and documents

Publications

  • Boccatonda A, Gentilini S, Zanata E, Simion C, Serra C, Simioni P, Piscaglia F, Campello E, Ageno W. Portal Vein Thrombosis: State-of-the-Art Review. J Clin Med. 2024 Mar 6;13(5):1517. doi: 10.3390/jcm13051517. PubMed 38592411 ↗
  • Cohen O, Caiano LM, Tufano A, Ageno W. Cancer-Associated Splanchnic Vein Thrombosis. Semin Thromb Hemost. 2021 Nov;47(8):931-941. doi: 10.1055/s-0040-1722607. Epub 2021 Jun 11. PubMed 34116580 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 103 non-industry observational studies under Venous Thrombosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 99. This study's planned 12 months is below that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 9, 2026
StartActual
Dec 14, 2025
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329725
Lead sponsor
Sohag University
Responsible party
Fatma mohamed Ahmed Anwer (Principal Investigator, Sohag University) — Principal investigator
First posted
Jan 9, 2026
Start date
Dec 14, 2025
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

Mahmoud I Yousef, Associate Prof.
study chair · Sohag University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion